Used in research for its potential rapid-acting antidepressant effects, particularly in treatment-resistant depression. It acts as an NMDA receptor antagonist, similar to ketamine, and is studied for its ability to improve mood within hours after administration. Investigated in clinical settings to evaluate its efficacy and safety profile in managing major depressive disorder and suicidal ideation. Its development aims to provide a non-ketamine option with a favorable side effect and abuse liability profile.